Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancerReport as inadecuate

Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer - Download this document for free, or read online. Document in PDF available to download.

Radiation Oncology

, 9:47

Clinical Radiation Oncology


BackgroundWe sought to describe patterns of initial radiotherapy among non-metastatic prostate cancer PC patients by recurrence risk groups.

MethodsMedical records were abstracted for a sample of 9017 PC cases diagnosed in 2004 as a part of the Center for Disease Control and Prevention’s Prostate and Breast Patterns of Care Study in seven states. Non-metastatic PC cases are categorized as low-risk LR, intermediate-risk IR or high-risk HR groups based on pretreatment PSA, tumor stage, and Gleason score per 2002 NCCN guidelines. Univariate and multivariate analyses were employed to determine factors associated with the type and dose of radiotherapy by the risk groups.

ResultsOf the 9,017 patients, 3153 who received definitive radiotherapy either alone or in combination with hormone therapy HT were selected for in-depth analysis. Multivariate models showed that LR patients were more likely to receive seed implant brachytherapy BT than those in higher risk groups. Those in the IR group were most likely to receive external beam radiotherapy EBRT combined with BT or high-dose radiotherapy. Use of HT in combination with radiotherapy was more common in the IR and HR groups than for LR patients. Intensity modulated radiation treatment IMRT was used to treat 32.6% of PC patients treated with EBRT, with the majority 60.6% treated with high-dose radiotherapy.

ConclusionsRadiotherapy types and dosage utilization varied by PC risk groups. Patients in IR were more likely than those in LR or HR to receive high-dose radiotherapy. IMRT was used in about one third of patients to deliver high-dose radiotherapy.

KeywordsProstate cancer Radiotherapy Patterns of care study AbbreviationsPCProstate cancer

IMRTIntensity modulated radiation treatment

LRLow risk

IRIntermediate risk

HRHigh risk

NCCNNational comprehensive cancer network

HTHormone therapy


EBRTExternal beam radiotherapy

NPCRNational program of cancer registries

CDCCenter for disease control and prevention

POC BPProstate cancer data quality and patterns of care study

PSAProstate specific antigen

GSGleason score

ACE-27Adult comorbidity evaluation-27


CIConfidence intervals

OROdds ratios.

Electronic supplementary materialThe online version of this article doi:10.1186-1748-717X-9-47 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Dian Wang - Alex Ho - Ann S Hamilton - Xiao-Cheng Wu - Mary Lo - Steven Fleming - Michael Goodman - Trevor Thompson - Jea

Source: https://link.springer.com/

Related documents